GlaxoSmith Kline (NYSE:GSK) and Sanofi (NYSE:SNY) recently announced their intent to seek regulatory authorization for an adjuvanted recombinant protein-based COVID-19 vaccine. Now, GSK and its partner Medicago have received approval from Health Canada for another COVID-19 vaccine, which combines the former’s adjuvant technology with the latter’s plant-derived vaccine. Known as Covifenz, the vaccine makes use of plant-based virus-like…
Medicago and GSK partner on COVID-19 vaccine trial
The Canadian biotech firm Medicago (CVE:MDG) is hooking up GlaxoSmithKline (NYSE:GSK) on a study involving 30,000 participants. The Quebec City-based Medicago had recently announced promising data concerning its plant-based vaccine candidate. Medicago’s vaccine is unique in that it uses virus-like particles that resemble the structure of the novel coronavirus but contain no genetic material from the virus. …